| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,810,872 ) |
| | 2024 | 2024 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 000 | 1 | NIH | 9/10/2024 | $1,496,402 |
| | 2024 | 2024 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01DK133709 | Continuation of The Collaborative Islet Transplantation Registry (CITR) | 000 | 3 | NIH | 7/25/2024 | $314,470 |
| | 2024 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 5 | NIH | 2/23/2024 | $0 |
| | 2024 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 001 | 5 | NIH | 8/21/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,489,493 ) |
| | 2023 | 2023 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01DK133709 | Continuation of The Collaborative Islet Transplantation Registry (CITR) | 000 | 2 | NIH | 8/9/2023 | $703,698 |
| | 2023 | 2023 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 000 | 1 | NIH | 9/21/2023 | $1,827,171 |
| | 2023 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 5 | NIH | 8/21/2023 | $0 |
| | 2023 | 2018 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL146019 | Support Services for the NHLBI-Sponsored Data Science Institutional Review Board | 000 | 1 | NIH | 5/17/2023 | $0 |
| | 2023 | 2017 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST, STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UC4DK114839 | Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) | 000 | 1 | NIH | 10/1/2022 | -$41,376 |
|
| Issue Date FY: 2022 ( Subtotal = $3,505,697 ) |
| | 2022 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01DK133709 | Continuation of The Collaborative Islet Transplantation Registry (CITR) | 000 | 1 | NIH | 9/14/2022 | $734,596 |
| | 2022 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 000 | 1 | NIH | 9/9/2022 | $1,812,534 |
| | 2022 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL146019 | Support Services for the NHLBI-Sponsored Data Science Institutional Review Board | 000 | 1 | NIH | 7/27/2022 | $643,082 |
| | 2022 | 2022 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 5 | NIH | 8/29/2022 | $315,485 |
| | 2022 | 2017 | THE EMMES COMPANY LLC | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | R01DA041328 | Comparison of Substance Use Screeners in Assessing Prescription Drug Abuse and Other Illicit Drug Use among Pregnant Women | 000 | 3 | NIH | 5/23/2022 | $0 |
| | 2022 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UC4DK114839 | Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) | 000 | 1 | NIH | 10/27/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,148,180 ) |
| | 2021 | 2021 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 001 | 4 | NIH | 5/20/2021 | $283,361 |
| | 2021 | 2021 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 004 | 1 | NIH | 8/13/2021 | $1,864,819 |
| | 2021 | 2020 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 3 | NIH | 4/6/2021 | $0 |
| | 2021 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UC4DK114839 | Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) | 000 | 1 | NIH | 8/26/2021 | $0 |
| | 2021 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 000 | 1 | NIH | 5/24/2021 | $0 |
| | 2021 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 001 | 1 | NIH | 7/1/2021 | $0 |
| | 2021 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 002 | 1 | NIH | 7/16/2021 | $0 |
| | 2021 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL142340 | Sickle Cell Disease Cure Initiative (SCDC) | 003 | 1 | NIH | 8/13/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $433,755 ) |
| | 2020 | 2020 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 3 | NIH | 6/1/2020 | $431,909 |
| | 2020 | 2018 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 000 | 5 | NIH | 9/28/2020 | $0 |
| | 2020 | 2017 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | R01DA041328 | Comparison of Substance Use Screeners in Assessing Prescription Drug Abuse and Other Illicit Drug Use among Pregnant Women | 001 | 3 | NIH | 4/6/2020 | $1,846 |
|
| Issue Date FY: 2019 ( Subtotal = $433,078 ) |
| | 2019 | 2019 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 001 | 2 | NIH | 7/26/2019 | $433,262 |
| | 2019 | 2018 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 1 | NIH | 5/24/2019 | $0 |
| | 2019 | 2018 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 000 | 5 | NIH | 5/13/2019 | $0 |
| | 2019 | 2016 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01NS050659 | MONEAD Data and Statistical Center | 001 | 10 | NIH | 2/18/2019 | $166 |
| | 2019 | 2016 | EMMES COMPANY, LLC, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01NS050659 | MONEAD Data and Statistical Center | 000 | 10 | NIH | 11/5/2018 | -$350 |
|
| Issue Date FY: 2018 ( Subtotal = $2,197,548 ) |
| | 2018 | 2018 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 000 | 5 | NIH | 3/28/2018 | $1,059,710 |
| | 2018 | 2018 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | OT2HL146019 | Support Services for the NHLBI-Sponsored Data Science Institutional Review Board | 000 | 1 | NIH | 4/27/2018 | $494,132 |
| | 2018 | 2018 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UG1EY028517 | Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein Occlusion | 000 | 1 | NIH | 6/13/2018 | $474,723 |
| | 2018 | 2017 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | R01DA041328 | Comparison of Substance Use Screeners in Assessing Prescription Drug Abuse and Other Illicit Drug Use among Pregnant Women | 002 | 3 | NIH | 9/7/2018 | $168,983 |
| | 2018 | 2016 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01AI066560 | CoFAR Statistical and Clinical Coordinating Center | 001 | 10 | NIH | 2/21/2018 | $2 |
| | 2018 | 2015 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01AI066560 | CoFAR Statistical and Clinical Coordinating Center | 000 | 10 | NIH | 2/21/2018 | -$2 |
|
| Issue Date FY: 2017 ( Subtotal = $3,402,349 ) (Continued on the next page) |
| | 2017 | 2017 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | UC4DK114839 | Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) | 000 | 1 | NIH | 9/1/2017 | $2,734,163 |
| | 2017 | 2017 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1737 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 002 | 4 | NIH | 3/29/2017 | $1,150,820 |
| | 2017 | 2016 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U01NS050659 | MONEAD Data and Statistical Center | 001 | 10 | NIH | 4/12/2017 | $410,439 |
| | 2017 | 2016 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 001 | 3 | NIH | 2/3/2017 | $42,516 |
| | 2017 | 2015 | EMMES CORPORATION, THE | 401 N WASHINGTON ST STE 700 | ROCKVILLE | MD | 20850-1785 | MONTGOMERY | USA | U10EY023529 | SCORE2 Comparative Trial (SCT) | 000 | 2 | NIH | 2/3/2017 | -$42,516 |
|
